Turbine fuel composition exhibiting improved cold properties

Details for Australian Patent Application No. 2006237132 (hide)

Owner BASF Aktiengesellschaft

Inventors Mahling, Frank-Olaf; Pfeiffer, Thomas; Ahlers, Wolfgang; Posselt, Dietmar

Agent Watermark

Pub. Number AU-B-2006237132

PCT Pub. Number WO2006/111326

Priority 05021172.1 28.09.05 EP; 05008420.1 18.04.05 EP

Filing date 13 April 2006

Wipo publication date 26 October 2006

Acceptance publication date 23 June 2011

International Classifications

C10L 1/18 (2006.01) Liquid carbonaceous fuels

C08F 220/16 (2006.01) Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide, or nitrile thereof

C08L 23/08 (2006.01) Compositions of macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds

C10L 10/14 (2006.01) Use of additives to fuels or fires for particular purposes - for improving low temperature properties

C10L 10/16 (2006.01) Use of additives to fuels or fires for particular purposes

Event Publications

8 November 2007 PCT application entered the National Phase

  PCT publication WO2006/111326 Priority application(s): WO2006/111326

23 June 2011 Application Accepted

  Published as AU-B-2006237132

20 October 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006237133-Preparation containing at least one conazole fungicide a further fungicide and a stabilising copolymer

2006237127-Azole derivatives in the form of Lipase and Phospholipase inhibitors